SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare gets warning letter from US FDA

31 Dec 2015 Evaluate

Cadila Healthcare has received a Warning Letter issued by the US FDA relating to its Moraiya formulation facility and Ahmedabad API facility (Zyfine). The company will respond to US FDA to address the observations within the statutory time permitted in the letter. The company is committed to resolve all the issues and revamp its quality systems and processes as the top most priority.

Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

904.15 2.50 (0.28%)
05-May-2026 09:58 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1802.85
Dr. Reddys Lab 1282.25
Cipla 1321.95
Zydus Lifesciences 904.15
Lupin 2347.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×